The Trump Administration struck a deal with Eli Lilly and Novo Nordisk to lower the prices of their groundbreaking GLP-1 receptor agonist medications, tirzepatide (Zepbound, Mounjaro; Eli Lilly) and semaglutide (Ozempic, Wegovy; Novo Nordisk), for Medicare and Medicaid beneficiaries starting in January 2026. All companies released a news release and had a press conference at the White House to share the news.
The Trump Administration is pressuring the pharmaceutical industry to align with “most favored nation” (MFN) groupings, ensuring that drugs marketed in the United States are priced at a level equivalent to the frequently lower pricing available in other developed nations.
What Is the Trump GLP-1 Pricing Deal?
In a major announcement at the White House, Trump, alongside executives from Eli Lilly and Novo Nordisk, unveiled new agreements aimed at drastically reducing the cost of GLP-1 medications. Under this plan, consumers will soon pay between $245 and $350 per month for popular obesity drugs, such as Wegovy and Zepbound, compared to the current average of over $1,000 per month without insurance.
The deal expands both companies’ access to Medicare and Medicaid, extending coverage for older adults and low-income Americans. As part of the agreement, Eli Lilly will also receive a three-year tariff exemption, ensuring stable pricing during the rollout phase.
Officials estimate that 10% of Medicare beneficiaries will now qualify for GLP-1 coverage, with a $50 copay under the new structure. The medications will be available at discounted prices through TrumpRx, a direct-to-consumer, government-run website launching in January 2026.
On TrumpRx, prices for Wegovy and Zepbound are expected to start around $350 per month, with a projected drop to $250 within two years.
Additionally, the lowest dose of the upcoming weight-loss pills from Novo Nordisk and Eli Lilly’s orforglipron will be sold at $149 for anyone buying them through Medicaid, Medicare, or TrumpRx. Zepbound injections will cost $299 for a starting dose.
Eli Lilly’s pill orforglipron may launch next year, while Novo Nordisk’s oral version of its obesity injectable Wegovy may be available by year’s end.
What Drugs Are Included and Who Qualifies
The Trump GLP-1 pricing deal covers several leading medications that have transformed the treatment of obesity and diabetes—Wegovy (semaglutide for obesity), Ozempic (semaglutide for diabetes), and Zepbound (tirzepatide). Future oral GLP-1 options, including Eli Lilly’s orforglipron, will also be part of the program once approved by the FDA.
Under the updated coverage, Medicare and Medicaid will now include GLP-1 medications for people who are overweight or obese and have related health conditions such as heart disease, kidney disease, hypertension, or sleep apnea.
Eligible patients will fall into three cohorts:
- Those who are overweight (BMI over 27) with prediabetes or cardiovascular disease.
- People with obesity (BMI over 30) who have uncontrolled hypertension, kidney disease, or heart failure.
- Patients with severe obesity (BMI over 35) who are at the highest risk for obesity-related complications.
Approximately 10% of Medicare beneficiaries are expected to qualify for coverage at launch. While this expansion marks significant progress, coverage for weight loss alone, without related medical conditions, remains limited until future policy changes broaden eligibility.
As one administration official explained, “We are constraining the access for patients that will benefit clinically from it. We’ve worked very hard to strike a balance between broad access and ensuring it’s available to those who will benefit the most.”
The Reality: Affordability Still Matters
While the Trump GLP-1 pricing deal marks a major step forward, affordability and accessibility remain ongoing challenges. Even with prices dropping to $250–$350 per month, many Americans may still find these treatments financially out of reach, especially those without Medicare, Medicaid, or comprehensive private insurance.
Experts also note that it’s still unclear how many people will qualify under the new deal. Currently, Medicare covers Wegovy for people at high risk of heart disease and Zepbound for those with sleep apnea, but not for weight loss alone, as federal law limits Medicare from covering drugs used exclusively for weight loss. Ozempic remains covered only for diabetes treatment.
These uncertainties mean that many patients may still face coverage gaps or delays in accessing care. And while cash-pay programs like Costco’s $499 Wegovy and Walmart’s Zepbound offer additional options, they’re still too costly for many people.
Affordable Alternative to Wegovy and Zepbound
While new federal pricing and coverage changes are on the horizon, NP2GO is already helping patients access affordable GLP-1 treatments without waiting for policy rollouts to take effect.
Our compounded semaglutide and tirzepatide programs provide a safe, lower-cost alternative to brand-name medications like Wegovy and Zepbound, without compromising quality and results.
Usually, compounders create medications that require customization, such as when a patient has an allergy to a certain ingredient or requires other changes to be made. However, the law also allows compounding when medications are in limited supply.
For several years, GLP-1 manufacturers struggled to meet high demand, leading to the emergence of an entire industry for off-brand, compounded GLP-1s.
While the shortages have now resolved, some providers, including the NP2GO, still offer the compounded versions of the medications at a significantly lower price than Novo Nordisk and Eli Lily.
We ensure nationwide access to care through telehealth visits and a team of licensed providers available in 28+ states.
We offer transparent, flat-rate pricing and accept Flexible Spending (FSA) and Health Savings Accounts (HSA), so you always know what you’re paying for.
If you’re struggling with the high costs of brand-name GLP-1s or waiting for Medicare and Medicaid coverage to take effect, our compounded medications serve as an accessible bridge to proven, effective weight loss therapy.
Beyond prescriptions, NP2GO provides personalized support, including hormone consults, nutritional guidance, and customized dose adjustments, to help you achieve sustainable, long-term results.
FAQs About Trump’s GLP-1 Deal
How much will Zepbound cost when purchased through TrumpRx?
Under the TrumpRx initiative, the average monthly cost of Zepbound is expected to start at around $350 and decrease to $250 within two years. The initiative also includes an oral GLP-1 pill, orforglipron, with starting doses expected to be at $149 per month once the FDA approves it.
What is TrumpRx?
TrumpRx is a government-run platform set to launch in early 2026, allowing consumers to buy prescription medications directly from manufacturers without going through insurance. The site will offer discounted “most favored nation” prices, similar to costs in other countries, and will be accessible to Medicaid beneficiaries.
What is Trump’s Wegovy price?
Under the new deal, the list price of Wegovy is set to drop to approximately $350 per month when purchased through TrumpRx, down from the previous retail price of over $1,000 per month.
Your Next Steps: Start Your GLP-1 Journey with NP2GO
The TrumpRx initiative and upcoming GLP-1 price reductions represent a major step toward making medical weight loss more accessible and affordable, a mission NP2GO has championed from the start.
If you’re uninsured or paying out of pocket, NP2GO’s compounded semaglutide and tirzepatide continue to offer a cost-effective alternative to expensive brand-name medications.
For those covered by Medicare or Medicaid, lower copays and expanded access are expected to be available soon. However, eligibility will depend on your specific BMI, medical conditions, and treatment needs.
Now is the perfect time to schedule a consultation with NP2GO to:
- Review your eligibility for semaglutide or tirzepatide.
- Compare compounded versus branded GLP-1 options and choose the one that fits your goals and budget.
- Explore hormone and metabolic balance assessments to create a holistic, medically supervised weight loss plan.
Whether you’re waiting for Medicare coverage to take effect or ready to begin your journey today, NP2GO makes it easy to start safely and affordably. Our experienced nurse practitioners provide personalized care plans using compounded semaglutide and tirzepatide, designed to fit your goals, budget, and health profile.
Take the first step toward lasting results. Book your consultation today and discover how NP2GO can help you achieve real, sustainable weight loss.